Table 1. Overexpression of RSPO and LGR in BC tumours and BC cell lines.
| Overexpression | RSPO1, n (%) | RSPO2, n (%) | RSPO3, n (%) | RSPO4, n (%) | Alla RSPO, n (%) | LGR4, n (%) | LGR5, n (%) | LGR6, n (%) | Alla LGR, n (%) |
|---|---|---|---|---|---|---|---|---|---|
|
Patient tumour samples | |||||||||
| Whole population (n=446) | 5 (1.1%) | 12 (2.7%) | 1 (0.2%) | 41 (9.2%) | 52 (11.6%) | 3 (0.6%) | 16 (3.6%) | 4 (0.9%) | 23 (5.1%) |
| TNBC subgroup (n=68) | 3 (4.4%) | 12 (17.6%) | 1 (1.5%) | 29 (42.6%) | 38 (55.8%) | 1 (1.5%) | 10 (14.7%) | 3 (4.4%) | 14 (20.6%) |
| Metaplastic cohort (n=28) | 0 (0%) | 13 (46%) | 0 (0%) | 12 (42.8%) | 18 (64%) | 0 (0%) | 9 (32.1%) | 0 (0%) | 9 (32.1%) |
|
Cancer cell lines | |||||||||
| Whole population (n=32) | 2 (6.2%) | 2 (6.2%) | 4 (12.5%) | 4 (12.5%) | 9 (28%) | 4 (12.5%) | 2 (6.2%) | 9 (28%) | 14 (43.8%) |
| TNBC subgroup (n=16) | 2 (12.5%) | 2 (12.5%) | 4 (25%) | 2 (12.5%) | 7 (43.7%) | 1 (6.3%) | 2 (12.5%) | 8 (50%) | 10 (62.5%) |
Abbreviations: LGR=leucine-rich repeat containing G protein-coupled receptor; TNBC=triple-negtive breast cancer.
a
Overexpression of at least one RSPO gene.